Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept to silence ACPA-expressing B cells in rheumatoid arthritis
2017-002878-38Phase 4Completed
- Sponsor
- Leiden University Medical Center
- Start
- Sep 2017
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of abatacept in rheumatoid arthritis (RA) (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Percentage of circulating ACPA-positive B cells expressing Ki-67 at week 24. Started Sep 2017; status: completed.
02
Drugs
abatacept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2017-002878-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002878-38.